According to Business Week, Carrington Laboratories Inc. has announced that early-stage trial data showed that its GelVac system for administering a powder vaccine through the nose consistently delivered doses, proved safe and was well-tolerated. The powder does not require refrigeration and allows for self-administration of a vaccine without injections. The substance changes from a liquid or a powder to a gel upon contact with body fluids.The company claims that the GelVac systems provides a potential solution to problems of refrigeration in delivering vaccines in developing countries. "We now plan to provide our data to potential domestic and international partners and, when appropriate, share them with the scientific and business communities," Chief Executive Carlton E. Turner said in a statement.
Topics
DISCLAIMER & PERMISSIONS
CGD's publications reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions. You may use and disseminate CGD's publications under these conditions.
